Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma

BACKGROUND: Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma. Adding other active agents may enhance treatment efficacy. METHODS: The primary objective of this factorial phase II study was to determine if one of 3 potential chemotherapy ag...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Penas-Prado, Marta, Hess, Kenneth R., Fisch, Michael J., Lagrone, Lore W., Groves, Morris D., Levin, Victor A., De Groot, John F., Puduvalli, Vinay K., Colman, Howard, Volas-Redd, Gena, Giglio, Pierre, Conrad, Charles A., Salacz, Michael E., Floyd, Justin D., Loghin, Monica E., Hsu, Sigmund H., Gonzalez, Javier, Chang, Eric L., Woo, Shiao Y., Mahajan, Anita, Aldape, Kenneth D., Yung, W. K. Alfred, Gilbert, Mark R.
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2015
主題:
Clinical Investigations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4288521/
https://ncbi.nlm.nih.gov/pubmed/25239666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou155
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料